Indicated to address blood clot formation to support stroke prevention and alleviate the risk of venous thromboembolism in high-risk adult patients.
Mechanism of Action
Rivaroxaban works by blocking a specific protein in the blood called Factor Xa. Factor Xa is essential for the production of thrombin, which forms the physical structure of a clot. By inhibiting this protein, the drug slows the clotting process.
Route of Administration
Oral
Onset Time
2–4 hours
Duration
24 hours
Contraindications
Active major bleeding, Severe kidney disease, Liver disease with coagulation issues, Pregnancy
Severe Adverse Events
Serious internal bleeding, Spinal or epidural hematoma, Brain hemorrhage, Severe allergic reactions
Information for Rivaroxaban is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
